Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ's MedImmune sues Abbott over non-development and $50m payment deficit for RSV antibodies

This article was originally published in Scrip

Executive Summary

Another drug development pact has resulted in a heated dispute – as AstraZeneca subsidiary MedImmune has sued Abbott after the Illinois company unilaterally halted seeking approval of the respiratory syncytial virus treatment motavizumab outside the US. Exacerbating the dispute, Abbott also claims that the absence of development for motavizumab means it can reduce what it pays for exclusive ex-US rights to distribute MedImmune's first-generation RSV product, Synagis (palivizumab). MedImmune disagrees.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel